JP2014509868A5 - - Google Patents

Download PDF

Info

Publication number
JP2014509868A5
JP2014509868A5 JP2014501270A JP2014501270A JP2014509868A5 JP 2014509868 A5 JP2014509868 A5 JP 2014509868A5 JP 2014501270 A JP2014501270 A JP 2014501270A JP 2014501270 A JP2014501270 A JP 2014501270A JP 2014509868 A5 JP2014509868 A5 JP 2014509868A5
Authority
JP
Japan
Prior art keywords
expression
seq
level
kit
gene product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014501270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014509868A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/030309 external-priority patent/WO2012135008A1/en
Publication of JP2014509868A publication Critical patent/JP2014509868A/ja
Publication of JP2014509868A5 publication Critical patent/JP2014509868A5/ja
Pending legal-status Critical Current

Links

JP2014501270A 2011-03-26 2012-03-23 癌の予後のための遺伝子発現予測因子 Pending JP2014509868A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161467999P 2011-03-26 2011-03-26
US61/467,999 2011-03-26
PCT/US2012/030309 WO2012135008A1 (en) 2011-03-26 2012-03-23 Gene expression predictors of cancer prognosis

Publications (2)

Publication Number Publication Date
JP2014509868A JP2014509868A (ja) 2014-04-24
JP2014509868A5 true JP2014509868A5 (2) 2015-05-07

Family

ID=46931859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014501270A Pending JP2014509868A (ja) 2011-03-26 2012-03-23 癌の予後のための遺伝子発現予測因子

Country Status (5)

Country Link
US (2) US20140113297A1 (2)
EP (1) EP2691547A4 (2)
JP (1) JP2014509868A (2)
CA (1) CA2831074A1 (2)
WO (1) WO2012135008A1 (2)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058018A2 (en) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
AU2009253675A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US9605319B2 (en) 2010-08-30 2017-03-28 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
WO2014003580A1 (en) * 2012-06-28 2014-01-03 Caldera Health Ltd Targeted rna-seq methods and materials for the diagnosis of prostate cancer
EP2885640B1 (en) 2012-08-16 2018-07-18 Genomedx Biosciences, Inc. Prostate cancer prognostics using biomarkers
CA2891653A1 (en) 2012-11-16 2014-05-22 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US20160032395A1 (en) * 2013-03-14 2016-02-04 Elai Davicioni Cancer biomarkers and classifiers and uses thereof
US20140336280A1 (en) * 2013-03-14 2014-11-13 Neogenomics Laboratories, Inc. Compositions and methods for detecting and determining a prognosis for prostate cancer
CA2947624A1 (en) 2014-05-13 2015-11-19 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US11174518B2 (en) 2015-10-05 2021-11-16 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
WO2018132916A1 (en) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
CA3055925A1 (en) 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
AU2018266733A1 (en) 2017-05-12 2020-01-16 Veracyte, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY
US11083127B2 (en) 2018-05-09 2021-08-10 Deere & Company Seeding machine to provide transverse tramlines
EP4181926A4 (en) * 2020-07-15 2024-08-21 Queensland University Of Technology DETERMINING THE RESPONSIVENESS OF A CANCER TO A TREATMENT

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004258085B2 (en) * 2003-07-10 2010-05-27 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US20080275652A1 (en) * 2005-05-13 2008-11-06 Universite Libre De Bruxelles Gene-based algorithmic cancer prognosis
US7914988B1 (en) * 2006-03-31 2011-03-29 Illumina, Inc. Gene expression profiles to predict relapse of prostate cancer
AU2007284651B2 (en) * 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
US8470534B2 (en) * 2006-12-01 2013-06-25 Erik S. Knudsen Methods of predicting resistance or sensitivity to therapies for cancer
AU2009253675A1 (en) * 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US20090298082A1 (en) * 2008-05-30 2009-12-03 Klee George G Biomarker panels for predicting prostate cancer outcomes
EP2315858A2 (en) * 2008-07-08 2011-05-04 Source Precision Medicine, Inc. Gene expression profiling for predicting the survivability of prostate cancer subjects
WO2010080933A1 (en) * 2009-01-07 2010-07-15 Myriad Genetics, Inc Cancer biomarkers
WO2010129965A1 (en) * 2009-05-08 2010-11-11 The Regents Of The University Of California Cancer specific mitotic network
MX337650B (es) * 2009-11-23 2016-03-14 Genomic Health Inc Metodos para predecir el desenlace clinico del cancer.
EP3812469A1 (en) * 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis

Similar Documents

Publication Publication Date Title
JP2014509868A5 (2)
Maltseva et al. High-throughput identification of reference genes for research and clinical RT-qPCR analysis of breast cancer samples
KR101562644B1 (ko) 직장결장암용 예후 예측
ES2525382T3 (es) Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino
CA2776751C (en) Methods to predict clinical outcome of cancer
JP6219824B2 (ja) びまん性大細胞型b細胞性リンパ腫(dlbcl)患者における抗−cd20療法に対する応答の予測
KR20140105836A (ko) 다유전자 바이오마커의 확인
JP2006506945A (ja) 遺伝子発現プロフィールを使用する非小細胞肺癌の診断および処置のための方法および組成物
SG192108A1 (en) Colon cancer gene expression signatures and methods of use
JP2019004907A (ja) メラノーマ癌の予後予測
AU2004211955A1 (en) Gene expression markers for response to EGFR inhibitor drugs
JP2006506093A5 (2)
JP2014509868A (ja) 癌の予後のための遺伝子発現予測因子
US20160186270A1 (en) Signature of cycling hypoxia and use thereof for the prognosis of cancer
Wu et al. Systematic analysis of transcribed loci in ENCODE regions using RACE sequencing reveals extensive transcription in the human genome
Zhang et al. Comprehensive analysis of prognostic value of MEX3A and its relationship with immune infiltrates in ovarian cancer
US20180046754A1 (en) Normalization methods for measuring gene copy number and expression
CN108474041A (zh) 使用遗传标记的甲基化状态区分转移性-致死性前列腺癌与惰性前列腺癌
Rajawat Transcriptomics
EP3196316B1 (en) METHOD AND DEVICE FOR COMPARATIVE ANALYSIS OF miRNA EXPRESSION LEVEL
US20230340611A1 (en) Biomarkers For Immune Checkpoint Inhibitors Treatment
CN110387411A (zh) 用于检测狼疮性肾炎或评估狼疮性肾炎风险的方法及其应用
KR20230028619A (ko) 아토피성 피부염 진단용 바이오마커 및 이의 용도
EP2823059A2 (en) Gene signatures associated with efficacy of postmastectomy radiotherapy in breast cancer
US20170051332A1 (en) Methods and compositions for detecting expression of target genes